Sunshine Biopharma, Inc.  

(Public, OTCMKTS:SBFM)   Watch this stock  
Find more results for OTC:SBFM
-0.012 (-9.62%)
Delayed:   11:49AM EDT
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.12 - 0.13
52 week 0.10 - 0.29
Open 0.12
Vol / Avg. 86,500.00/32,381.00
Mkt cap 7.36M
P/E     -
Div/yield     -
EPS -0.03
Shares 62.68M
Beta 19.27
Inst. own     -

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -3902.08% -3001.24%
Return on average equity - -7944.77%
Employees 3 -
CDP Score - -


3rd Floor, 469 Jean-Talon West
+1-514-7649698 (Phone)
+1-514-7649699 (Fax)

Website links


Sunshine Biopharma, Inc. is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company´┐Żs lead compound, Adva-27a is a multi-purpose anti-tumor. Its drug candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer. As of December 31, 2011, the Company planned to conduct its Phase I clinical trials for Adva-27a. In July 2014, the Company formed Sunshine Biopharma Canada Inc.

Officers and directors

Steve N. Slilaty Chairman of the Board, President, Chief Executive Officer
Age: 60
Camille Sebaaly Chief Financial Officer, Secretary, Director
Age: 53
Michele Di Turi Chief Operating Officer, Director
Age: 35